Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

The ‘real-world’ patient population of metastatic melanoma is not fully represented in clinical trials investigating checkpoint inhibitors. We described therapy discontinuation in an unselected population-based cohort of adults with metastatic melanoma who started therapy with pembrolizumab, nivolum...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado, Marina Amaral de Ávila, de Moura, Cristiano Soares, Chan, Kelvin, Curtis, Jeffrey R., Hudson, Marie, Abrahamowicz, Michal, Jamal, Rahima, Pilote, Louise, Bernatsky, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471311/
https://www.ncbi.nlm.nih.gov/pubmed/32884119
http://dx.doi.org/10.1038/s41598-020-71788-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471311/
https://www.ncbi.nlm.nih.gov/pubmed/32884119
http://dx.doi.org/10.1038/s41598-020-71788-z

Ejemplares similares